DUBLIN--(BUSINESS WIRE)--Jan 8, 2020--

The "Male Infertility - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

This latest Pharmaceutical and Healthcare disease pipeline guide Male Infertility - Pipeline Review, H2 2019, provides an overview of the Male Infertility (Male Health) pipeline landscape.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Male Infertility - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 4, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Infertility (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Male Infertility - Overview
  • Male Infertility - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Male Infertility - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Male Infertility - Companies Involved in Therapeutics Development
  • Aprilbio Co Ltd
  • Beijing Fogangren Bio-Pharm Tech Co Ltd
  • Cadila Healthcare Ltd
  • Health Ever Bio-Tech Co Ltd
  • Igyxos SA
  • Park Active Molecules
  • Prokrea BCN SL
  • St George Street Capital Ltd
  • Male Infertility - Drug Profiles
  • Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile
  • Drug for Male Infertility - Drug Profile
  • follicle stimulating hormone biobetter - Drug Profile
  • FSH-01 - Drug Profile
  • MCS-5 - Drug Profile
  • Monoclonal Antibody for Men and Women Infertility - Drug Profile
  • PAM-8 - Drug Profile
  • pentoxifylline - Drug Profile
  • Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Drug Profile
  • Small Molecule to Activate Telomerase for Men Infertility and Women Infertility - Drug Profile
  • trequinsin - Drug Profile
  • Male Infertility - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8qapos

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/08/2020 04:58 AM/DISC: 01/08/2020 04:58 AM

Copyright Business Wire 2020.